Frazier Lifesciences (FLAC) to Combine with NewAmsterdam in $326M Deal
Frazier Lifesciences (NASDAQ:FLAC) has entered into a definitive agreement to combine with biotech firm NewAmsterdam Pharma Holding at an enterprise value of $326 million. Netherlands-based NewAmsterdam is developing a range of drugs aimed at reducing patient cholesterol levels suffering from liver, heart and brain disorders. The combined company is expected to trade on the NasdaqRead More